Skip to content

AMG 133

DRUG13 trials

Sponsors

Amgen Inc., Amgen

Conditions

"Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweightChronic Weight ManagementHealthy ParticipantsHepatic ImpairmentModerate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesityObesityOverweight

Phase 1

Phase 2

Phase 3

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)
Active, not recruitingCTIS2024-515524-36-00
Amgen Inc.Chronic Weight Management
Start: 2025-05-30Target: 1050Updated: 2025-09-18
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)
Active, not recruitingCTIS2024-515523-11-00
Amgen Inc.Chronic Weight Management
Start: 2025-06-09Target: 404Updated: 2025-09-25
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
RecruitingCTIS2024-516652-18-00
Amgen Inc.Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight
Start: 2025-10-10Target: 5564Updated: 2025-11-24
A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)
Not yet recruitingCTIS2025-522699-94-00
Amgen Inc.Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity
Target: 97Updated: 2026-01-30
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-1)
Not yet recruitingCTIS2025-522703-14-00
Amgen Inc."Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"
Target: 45Updated: 2026-02-10